Transition Therapeutics Inc (NASDAQ:TTHI)

6.25
Data as of Jul 25
 -0.14 / -2.19%
Today’s Change
3.93
Today|||52-Week Range
8.22
+9.84%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$200.0M

Company Description

Transition Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapeutics for disease indications with large markets. It operates through research and development of therapeutic agents segment. The company's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

Contact Information

Transition Therapeutics, Inc.
101 College Street
Toronto Ontario M5G 1L7
P:(416) 260-7770
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Tony F. CruzChairman & Chief Executive Officer
Carl DamianiChief Operating Officer
Nicole Rusaw-GeorgeChief Financial Officer
Aleksandra PastrakVP-Clinical Development & Medical Officer
Bruce P. ConnopVP-Non Clinical & Pharmaceutical Development

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.